Urve Paaver

Prof. Dr. Urve Paaver


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
UPUrve Paaver
Urve Paaver
Jyrki HeinämäkiJyrki Heinämäki
Jyrki Heinämäki
ILIvo Laidmäe
Ivo Laidmäe
ALAndres Lust
Andres Lust
JKJekaterina Kozlova
Jekaterina Kozlova
Karin KogermannKarin Kogermann
Karin Kogermann

29 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
TDThuan Thi Duong
Thuan Thi Duong
AIAntti Isomäki
Antti Isomäki
UPUrve Paaver
Urve Paaver
ILIvo Laidmäe
Ivo Laidmäe
ATArvo Tõnisoo
Arvo Tõnisoo
TPThi-Minh-Hue Pham
Thi-Minh-Hue Pham
Berberine (BBR) is a poorly water-soluble quaternary isoquinoline alkaloid of plant origin with potential uses in the drug therapy of hypercholesterolemia. To tackle the limitations associated with the oral therapeutic use of BBR (such as a first-pass metabolism and poor absorption), BBR-loaded liposomes were fabricated by ethanol-injection and thin-film hydration methods. The size and size distribution, polydispersity index (PDI), solid-state properties, entrapment efficiency (EE) and in vitro drug release of liposomes were investigated. The BBR-loaded liposomes prepared by ethanol-injection and thin-film hydration methods presented an average liposome size ranging from 50 nm to 244 nm and from 111 nm to 449 nm, respectively. The PDI values for the liposomes were less than 0.3, suggesting a narrow size distribution. The EE of liposomes ranged from 56% to 92%. Poorly water-soluble BBR was found to accumulate in the bi-layered phospholipid membrane of the liposomes prepared by the thin-film hydration method. The BBR-loaded liposomes generated by both nanofabrication methods presented extended drug release behavior in vitro. In conclusion, both ethanol-injection and thin-film hydration nanofabrication methods are feasible for generating BBR-loaded oral liposomes with a uniform size, high EE and modified drug release behavior in vitro.

20 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
UPUrve Paaver
Urve Paaver
ITIngrid Tamm
Ingrid Tamm
ILIvo Laidmäe
Ivo Laidmäe
ALAndres Lust
Andres Lust
KKKalle Kirsimäe
Kalle Kirsimäe
Jyrki HeinämäkiJyrki Heinämäki
Jyrki Heinämäki
Electrospinning is an effective method in preparing polymeric nanofibrous drug delivery systems (DDSs) for topical wound healing and skin burn therapy applications. The aim of the present study was to investigate a new synthetic graft copolymer (Soluplus) as a hydrophilic carrier polymer in electrospinning of nanofibrous DDSs. Soluplus (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG)) was applied in the nonwoven nanomats loaded with piroxicam (PRX) as a poorly water-soluble drug. Raman spectroscopy, X-ray powder diffraction, differential scanning calorimetry, and scanning electron microscopy (SEM) were used in the physical characterization of nanofibrous DDSs. According to the SEM results, the drug-loaded PCL-PVAc-PEG nanofibers were circular in cross-section with an average diameter ranging from 500 nm up to 2 µm. Electrospinning stabilized the amorphous state of PRX. In addition, consistent and sustained-release profile was achieved with the present nanofibrous DDSs at the physiologically relevant temperature and pH applicable in wound healing therapy. In conclusion, electrospinning can be used to prepare nanofibrous DDSs of PCL-PVAc-PEG graft copolymer (Soluplus) and to stabilize the amorphous state of a poorly water-soluble PRX. The use of this synthetic graft copolymer can open new options to formulate nanofibrous DDSs for wound healing.

1 July 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
UPUrve Paaver
Urve Paaver
ALAndres Lust
Andres Lust
SMSabiruddin Mirza
Sabiruddin Mirza
JRJukka Rantanen
Jukka Rantanen
PVPeep Veski
Peep Veski
Karin KogermannKarin Kogermann
Karin Kogermann

17 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NSNiklas Sandler
Niklas Sandler
FSFarnaz Shokraneh
Farnaz Shokraneh
MBMahsa Bahman
Mahsa Bahman
JLJulius Lahtinen
Julius Lahtinen
NHNiko Hassinen
Niko Hassinen
FBFabien Bruno
Fabien Bruno
Pharmacy compounding, the art and science of preparing customized medications to meet individual patient needs, is on the verge of transformation. Traditional methods of compounding often involve manual and time-consuming processes, presenting challenges in terms of consistency, dosage accuracy, quality control, contamination, and scalability. However, the emergence of cutting-edge technologies has paved a way for a new era for pharmacy compounding, promising to redefine the way medications are prepared and delivered as pharmacy-tailored personalized medicines. In this multi-site study, more than 30 hospitals and community pharmacies from eight countries in Europe utilized a novel automated dosing approach inspired by 3D printing for the compounding of non-sterile propranolol hydrochloride tablets. CuraBlend® excipient base, a GMP-manufactured excipient base (pharma-ink) intended for automated compounding applications, was used. A standardized study protocol to test the automated dosing of tablets with variable weights was performed in all participating pharmacies in four different iterative phases. Integrated quality control was performed with an in-process scale and NIR spectroscopy supported by HPLC content uniformity measurements. In total, 6088 propranolol tablets were produced at different locations during this study. It was shown that the dosing accuracy of the process increased from about 90% to 100% from Phase 1 to Phase 4 by making improvements to the formulation and the hardware solutions. The results indicate that through this automated and quality controlled compounding approach, extemporaneous pharmacy manufacturing can take a giant leap forward towards automation and digital manufacture of dosage forms in hospital pharmacies and compounding pharmacies.

1 July 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Jyrki HeinämäkiJyrki Heinämäki
Jyrki Heinämäki
AHAnna Halenius
Anna Halenius
MPMaaja Paavo
Maaja Paavo
SASami Alakurtti
Sami Alakurtti
PPPauliina Pitkänen
Pauliina Pitkänen
JYJouko Yliruusi
Jouko Yliruusi